

Patient Access Start Guide

Follow the steps below to get started:



Healthcare provider submits prescription through e-prescribing platform or via fax to Nabriva RX Connect.

For e-prescribing, please use the following information for processing requests through EMR Systems:

Homescripts
500 Kirts Boulevard
Suite 300
Troy, MI 48084
NCPDP# 2374825
NPI# 1528362076

Please make sure prescription is complete, with all necessary clinical information included. Also, please be sure to include the patient's phone number so that shipment can be scheduled.

Fax scripts to: 1-833-406-0631



Nabriva RX Connect reviews the script, checks patient's insurance coverage, and assesses the patient's eligibility for copay assistance and the Patient Access Program (PAP).

- Copay assistance may be offered to eligible patients
- Healthcare providers must complete Patient Enrollment Form for patients eligible for PAP



Nabriva RX Connect will manage the fulfillment process and arrange shipment to your patient.

- Any questions about the shipment can be directed to 1-844-910-1252

Once paperwork is completed and insurance is verified/confirmed, prescription is typically shipped within 24 hours.



Nabriva RX Connect is available to assist you with securing access to XENLETA.

Support services include:

- **Copay Assistance**
Available for eligible patients with commercial insurance. Most patients pay no more than \$50 for each XENLETA prescription.
- **Healthcare Provider Education**
- **Benefit Investigations**
- **Prior Authorization Support**
- **Patient Assistance Program (PAP)**
Available for eligible patients who are US citizens. Nabriva Therapeutics US, Inc. will provide assistance (through in-kind product donations) to uninsured or underinsured patients who meet specific income requirements.
- **Direct shipment of prescription medication to patients**

Nabriva RX Connect provides reimbursement and access support for XENLETA.

Visit [XENLETA.com/access](https://www.xenleta.com/access) for more information.

All trademarks are the property of Nabriva Therapeutics Ireland DAC
Distributed by Nabriva Therapeutics US, Inc.
© 2019 Nabriva Therapeutics US, Inc.
PM-US-LEF-0202 DEC 2019

 **Xenleta**TM
(lefamulin)
150 mg injection | 600 mg tablets